Lack of association between the IL-10 gene polymorphisms and features of the metabolic syndrome

Journal of Investigative Medicine

Volumn 59, Issue 2, 2011, Pages 267-271

  Lu, Ming Ying ^a   Lakkakula, Bhaskar V K S ^b   Liao, Yi Chu ^a,c   Tsai, Pei Chien ^d,e   Yang, Yi Hsin ^d,e   Juo, Suh Hang Hank ^d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b SRI RAMACHANDRA UNIVERSITY   (India)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

IL 10; Metabolic syndrome; Single nucleotide polymorphism (SNP)

Indexed keywords

INTERLEUKIN 10; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRAIT; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; METABOLIC SYNDROME X; PATHOGENESIS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE CLASSIFICATION; MIDDLE AGED; MOLECULAR PATHOLOGY;

EID: 85008254109     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3182050a36     Document Type: Article

References (43)

1. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716. (Pubitemid 35403784)
2. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 2005;47:201-210. (Pubitemid 43471964)
3. Lee MS, Lin SC, Chang HY, et al. High prevalence of hyperuricemia in elderly Taiwanese. Asia Pac J Clin Nutr. 2005;14:285-292.
4. Lempiainen P, Mykkanen L, Pyorala K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123-128. (Pubitemid 29330009)
5. Kekalainen P, Sarlund H, Pyorala K, et al. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care. 1999;22:86-92. (Pubitemid 29028303)
6. Kuusisto J, Lempiainen P, Mykkanen L, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabeticmen. Diabetes Care. 2001;24:1629-1633. (Pubitemid 33716461)
7. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384-2389. (Pubitemid 33641926)
8. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334. (Pubitemid 32656163)
9. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006;580:2917-2921. (Pubitemid 43729162)
10. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21: 14431455.
11. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res. 2007;75:690-701. (Pubitemid 47238732)
12. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946. (Pubitemid 32756432)
13. Bullo M, Garcia-Lorda P, Megias I, et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003;11:525-531. (Pubitemid 41202413)
14. Chan JL, Heist K, DePaoli AM, et al. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409-1421. (Pubitemid 36554712)
15. Nishida M, Moriyama T, Sugita Y, et al. Interleukin-10 associates with adiponectin predominantly in subjects with metabolic syndrome. Circ J. 2007;71:1234-1238. (Pubitemid 47195339)
16. Moore PE, Lahiri T, Laporte JD, et al. Selected contribution: synergism between TNF-alpha and IL-1 beta in airway smooth muscle cells: implications for beta-adrenergic responsiveness. J Appl Physiol. 2001;91:1467-1474. (Pubitemid 32803947)
17. Kim HJ, Higashimori T, Park SY, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004;53:1060-1067. (Pubitemid 38436619)
18. van Exel E, Gussekloo J, de Craen AJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002;51:1088-1092. (Pubitemid 34438354)
19. Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab. 2003;88:1055-1058. (Pubitemid 36337756)
20. Choi KM, Ryu OH, Lee KW, et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75:235-240. (Pubitemid 44894605)
21. Westendorp RG, Langermans JA, Huizinga TW, et al. Genetic influence on cytokine production in meningococcal disease. Lancet. 1997;349:1912-1913. (Pubitemid 27270137)
22. Selzman CH, Meldrum DR, Cain BS, et al. Interleukin-10 inhibits postinjury tumor necrosis factor-mediated human vascular smooth muscle proliferation. J Surg Res. 1998;80:352-356. (Pubitemid 29019693)
23. Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30:526Y530.
24. Scarpelli D, Cardellini M, Andreozzi F, et al. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes. 2006;55:1529-1533. (Pubitemid 44195398)
25. Bassols J, Botas P, Moreno-Navarrete JM, et al. Environmental and genetic factors influence the relationship between circulating IL-10 and obesity phenotypes. Obesity (Silver Spring). 2010;18:611-618.
26. Upperman JS, Pillage G, Siddiqi MQ, et al. Dominance of high-producing interleukin 6 and low-producing interleukin 10 and interferon gamma alleles in glucose-6-phosphate dehydrogenase-deficient trauma patients. Shock. 2005;23:197-201. (Pubitemid 40293817)
27. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
28. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
29. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1Y8.
30. Tzeng JY, Wang CH, Kao JT, et al. Regression-based association analysis with clustered haplotypes through use of genotypes. Am J Hum Genet. 2006;78:231-242.
31. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
32. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-1830. (Pubitemid 38063705)
33. Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun. 2006;341:507-514. (Pubitemid 43152134)
34. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr Diabetes Rev. 2006;2:367-373. (Pubitemid 44734225)
35. Henkin L, Bergman RN, Bowden DW, et al. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Ann Epidemiol. 2003;13:211-217. (Pubitemid 36390342)
36. Fuentes L, Roszer T, Ricote M. Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages. Mediators Inflamm. 2010;2010:219583.
37. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93:S64-S73.
38. Esposito K, Giugliano G, Scuderi N, et al. Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg. 2006;118:1048-1057; discussion 1058Y1049. (Pubitemid 44412941)
39. Manigrasso MR, Ferroni P, Santilli F, et al. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J Clin Endocrinol Metab. 2005;90:5876-5879. (Pubitemid 41415505)
40. Kube D, Platzer C, von Knethen A, et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine. 1995;7:1-7.
41. Lim S, Crawley E, Woo P, et al. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet. 1998;352:113. (Pubitemid 28321327)
42. Crawley E, Kay R, Sillibourne J, et al. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-1108. (Pubitemid 29268946)
43. Brady J, Hayakawa Y, Smyth MJ, et al. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048-2058. (Pubitemid 38182350)